The most advanced DNA sequencer enhances the ELIXIR-IT research infrastructure
The NovaSeq X Plus, a cutting-edge DNA sequencer, boosts ELIXIR-IT's research capacity, allowing over 100 human genome sequences in 48 hours, solidifying our leadership in genomics and bioinformatics.
The Italian Node of ELIXIR (ELIXIR-IT), coordinated by the National Research Council (CNR), with its operational headquarters located at the Institute of Biomembranes, Bioenergetics, and Biotechnologies in Bari (CNR-IBIOM), is pleased to announce a significant development: the acquisition of the NovaSeq X Plus, the most advanced and efficacious DNA sequencer on the market that substantially enhances the research infrastructure.
This state-of-the-art technology enables the sequencing of over 100 human genomes within a 48-hour period, thereby solidifying ELIXIR-IT position as a leading center in the fields of genomics and bioinformatics on an international scale. The NovaSeq X Plus increases ELIXIR-IT capacity for high-throughput and precise genomic analysis, facilitating more rapid and comprehensive research outcomes.
This investment reflects ELIXIR-IT ongoing commitment to equipping the scientific community with the finest tools for genomic analysis, supporting a broad spectrum of research initiatives in biology, medicine, and biodiversity.



